Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Manufacturing cell and gene therapies at hospitals in dedicated, GMP-accredited facilities would overcome many of the technical and logistical challenges associated with decentralized production. So ...

Iovance chose Philadelphia for its manufacturing operations because of the region's proximity to airports and history of ...